Exelixis (EXEL) · zanzalintinib and atezolizumab
Date changed · A neutral label for the two timing statements. It says nothing about the program’s results.
Before
Stated timing: December 3, 2026
Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026
SEC original · filed · SEC filing
After
Stated timing: March 3, 2027
The updated Prescription Drug User Fee Act action date is March 3, 2027.
8-K · filed · SEC filing
Dots are filing dates. Bars show resolved calendar periods; timing wording stays as stated.
Sources: SEC original filed Aug 5, 2026; 8-K filed Sep 11, 2026.
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/EXEL-zanzalintinib-and-atezolizumab-2026-09-11, data as of Nov 4, 2026
https://www.orionbiotechai.com/changes/EXEL-zanzalintinib-and-atezolizumab-2026-09-11
Exelixis (EXEL) pipeline and stated timing · Calendar · Companies A–Z · Follow by RSS